Cargando…
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
[Image: see text] Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing damage to healthy cells and reducing systemic toxicity. Their design allows for higher doses of the cytoto...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655051/ https://www.ncbi.nlm.nih.gov/pubmed/37821099 http://dx.doi.org/10.1021/acs.bioconjchem.3c00374 |
_version_ | 1785147889898487808 |
---|---|
author | Sasso, Janet M. Tenchov, Rumiana Bird, Robert Iyer, Kavita A. Ralhan, Krittika Rodriguez, Yacidzohara Zhou, Qiongqiong Angela |
author_facet | Sasso, Janet M. Tenchov, Rumiana Bird, Robert Iyer, Kavita A. Ralhan, Krittika Rodriguez, Yacidzohara Zhou, Qiongqiong Angela |
author_sort | Sasso, Janet M. |
collection | PubMed |
description | [Image: see text] Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing damage to healthy cells and reducing systemic toxicity. Their design allows for higher doses of the cytotoxic drug to be administered, potentially increasing efficacy. They are currently among the most promising drug classes in oncology, with efforts to expand their application for nononcological indications and in combination therapies. Here we provide a detailed overview of the recent advances in ADC research and consider future directions and challenges in promoting this promising platform to widespread therapeutic use. We examine data from the CAS Content Collection, the largest human-curated collection of published scientific information, and analyze the publication landscape of recent research to reveal the exploration trends in published documents and to provide insights into the scientific advances in the area. We also discuss the evolution of the key concepts in the field, the major technologies, and their development pipelines with company research focuses, disease targets, development stages, and publication and investment trends. A comprehensive concept map has been created based on the documents in the CAS Content Collection. We hope that this report can serve as a useful resource for understanding the current state of knowledge in the field of ADCs and the remaining challenges to fulfill their potential. |
format | Online Article Text |
id | pubmed-10655051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-106550512023-11-17 The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress Sasso, Janet M. Tenchov, Rumiana Bird, Robert Iyer, Kavita A. Ralhan, Krittika Rodriguez, Yacidzohara Zhou, Qiongqiong Angela Bioconjug Chem [Image: see text] Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing damage to healthy cells and reducing systemic toxicity. Their design allows for higher doses of the cytotoxic drug to be administered, potentially increasing efficacy. They are currently among the most promising drug classes in oncology, with efforts to expand their application for nononcological indications and in combination therapies. Here we provide a detailed overview of the recent advances in ADC research and consider future directions and challenges in promoting this promising platform to widespread therapeutic use. We examine data from the CAS Content Collection, the largest human-curated collection of published scientific information, and analyze the publication landscape of recent research to reveal the exploration trends in published documents and to provide insights into the scientific advances in the area. We also discuss the evolution of the key concepts in the field, the major technologies, and their development pipelines with company research focuses, disease targets, development stages, and publication and investment trends. A comprehensive concept map has been created based on the documents in the CAS Content Collection. We hope that this report can serve as a useful resource for understanding the current state of knowledge in the field of ADCs and the remaining challenges to fulfill their potential. American Chemical Society 2023-10-11 /pmc/articles/PMC10655051/ /pubmed/37821099 http://dx.doi.org/10.1021/acs.bioconjchem.3c00374 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Sasso, Janet M. Tenchov, Rumiana Bird, Robert Iyer, Kavita A. Ralhan, Krittika Rodriguez, Yacidzohara Zhou, Qiongqiong Angela The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress |
title | The Evolving
Landscape of Antibody–Drug Conjugates:
In Depth Analysis of Recent Research Progress |
title_full | The Evolving
Landscape of Antibody–Drug Conjugates:
In Depth Analysis of Recent Research Progress |
title_fullStr | The Evolving
Landscape of Antibody–Drug Conjugates:
In Depth Analysis of Recent Research Progress |
title_full_unstemmed | The Evolving
Landscape of Antibody–Drug Conjugates:
In Depth Analysis of Recent Research Progress |
title_short | The Evolving
Landscape of Antibody–Drug Conjugates:
In Depth Analysis of Recent Research Progress |
title_sort | evolving
landscape of antibody–drug conjugates:
in depth analysis of recent research progress |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655051/ https://www.ncbi.nlm.nih.gov/pubmed/37821099 http://dx.doi.org/10.1021/acs.bioconjchem.3c00374 |
work_keys_str_mv | AT sassojanetm theevolvinglandscapeofantibodydrugconjugatesindepthanalysisofrecentresearchprogress AT tenchovrumiana theevolvinglandscapeofantibodydrugconjugatesindepthanalysisofrecentresearchprogress AT birdrobert theevolvinglandscapeofantibodydrugconjugatesindepthanalysisofrecentresearchprogress AT iyerkavitaa theevolvinglandscapeofantibodydrugconjugatesindepthanalysisofrecentresearchprogress AT ralhankrittika theevolvinglandscapeofantibodydrugconjugatesindepthanalysisofrecentresearchprogress AT rodriguezyacidzohara theevolvinglandscapeofantibodydrugconjugatesindepthanalysisofrecentresearchprogress AT zhouqiongqiongangela theevolvinglandscapeofantibodydrugconjugatesindepthanalysisofrecentresearchprogress AT sassojanetm evolvinglandscapeofantibodydrugconjugatesindepthanalysisofrecentresearchprogress AT tenchovrumiana evolvinglandscapeofantibodydrugconjugatesindepthanalysisofrecentresearchprogress AT birdrobert evolvinglandscapeofantibodydrugconjugatesindepthanalysisofrecentresearchprogress AT iyerkavitaa evolvinglandscapeofantibodydrugconjugatesindepthanalysisofrecentresearchprogress AT ralhankrittika evolvinglandscapeofantibodydrugconjugatesindepthanalysisofrecentresearchprogress AT rodriguezyacidzohara evolvinglandscapeofantibodydrugconjugatesindepthanalysisofrecentresearchprogress AT zhouqiongqiongangela evolvinglandscapeofantibodydrugconjugatesindepthanalysisofrecentresearchprogress |